Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)

Trial Profile

Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics; Therapeutic Use
  • Acronyms KEYNOTE-001
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 19 Jun 2018 Planned primary completion date changed from 2 Jul 2018 to 8 Oct 2018.
    • 05 Jun 2018 Results of four-year of survival data from patients with advanced NSCLC (n=550; as of 1 Sep 2017) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results of five-year survival (n=655; as 1 Sep 2017) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top